<DOC>
	<DOC>NCT01913847</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and clinical efficacy of HGP1207 (Sildenafil) in subjects with pulmonary hypertension associated with systolic heart failure.</brief_summary>
	<brief_title>Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Patients with a diagnosis of chronic heart failure (NYHA Class II and III) LVEF ≤ 40% Elevated systolic PAP: ≥ 40 mmHg Patients must be treated with an ACE inhibitor, ARB, betablocker, aldosterone antagonist at a stable dose for at least 4 weeks prior to visit 1 Patients with pulmonary hypertension associated with chronic obstructive pulmonary disease, interstitial lung disease, chronic thromboembolism or unclear/multifactorial mechanisms Patients who have received Nitrates/NO donor or Cytochrome P450 3A4 inhibitors within 30 days prior to visit 1 Patients who have received calcium channel blocker, endothelin receptor antagonist, prostacyclin analogues, phosphodiesterase 5 inhibitors within 90 days prior to visit 1 History of hypersensitivity or allergy to sildenafil or any excipients of its formulation Patients with hypertension (sitSBP &gt;170 mmHg or sitDBP&gt;100 mmHg) or hypotension (sitSBP&lt;90 mmHg or sitDBP&lt;50 mmHg) Patients with other medical condition (i.e.,alcoholism, drug abuse) that may cause the patient to be noncompliant with the protocol, confound the data interpretation Pregnant females or those of child bearing potential who have not had a negative pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>